Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04060199




Registration number
NCT04060199
Ethics application status
Date submitted
15/08/2019
Date registered
19/08/2019
Date last updated
27/10/2023

Titles & IDs
Public title
Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
Scientific title
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)
Secondary ID [1] 0 0
NS-065/NCNP-01-301
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Duchenne Muscular Dystrophy 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Viltolarsen
Treatment: Drugs - Placebo

Experimental: Viltolarsen - Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.

Placebo Comparator: Placebo - Patients amenable to exon 53 skipping will receive placebo intravenous (IV) infusions, weekly, for up to 48 weeks.


Treatment: Drugs: Viltolarsen
IV infusion

Treatment: Drugs: Placebo
IV infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
TTSTAND
Timepoint [1] 0 0
baseline to 48 weeks of treatment
Secondary outcome [1] 0 0
TTRW
Timepoint [1] 0 0
baseline to 48 weeks of treatment
Secondary outcome [2] 0 0
6MWT
Timepoint [2] 0 0
baseline to 48 weeks of treatment
Secondary outcome [3] 0 0
NSAA
Timepoint [3] 0 0
baseline to 48 weeks of treatment
Secondary outcome [4] 0 0
TTCLIMB
Timepoint [4] 0 0
baseline to 48 weeks of treatment
Secondary outcome [5] 0 0
Hand-held dynamometer
Timepoint [5] 0 0
baseline to 48 weeks of treatment

Eligibility
Key inclusion criteria
- Male = 4 years and < 8 years of age

- Confirmed DMD mutation(s) in the dystrophin gene that is amenable to skipping of exon
53 to restore the dystrophin mRNA reading frame

- Able to walk independently without assistive devices

- TTSTAND < 10 seconds

- Stable dose of glucocorticoid (GC) for at least 3 months prior to study entry and is
expected to remain on stable dose of GC treatment for the duration of the study

- Other inclusion criteria may apply
Minimum age
4 Years
Maximum age
7 Years
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
- Current or history of chronic systemic fungal or viral infections

- Acute illness within 4 weeks prior to the first dose of study drug

- Evidence of symptomatic cardiomyopathy (Note: Asymptomatic cardiac abnormality on
investigation would not be exclusionary)

- Allergy or hypersensitivity to the study drug or to any of its constituents

- Severe behavioral or cognitive problems that preclude participation in the study, in
the opinion of the investigator

- Previous or ongoing medical condition, medical history, physical findings or
laboratory abnormalities that could affect safety, make it unlikely that treatment and
follow-up will be correctly completed or impair the assessment of study results, in
the opinion of the investigator;

- Surgery within the 3 months prior to the first dose of study drug or surgery is
planned for anytime during the duration of the study

- Participant has positive test results for hepatitis B antigen, hepatitis C antibody or
human immunodeficiency virus (HIV)

- Currently taking any other investigational drug or has taken any other investigational
drug within 3 months prior to the first dose of study drug or within 5 times the
half-life of a medication, whichever is longer

- Previously enrolled in an interventional study of viltolarsen

- Currently taking any other exon skipping agent or has taken any other exon skipping
agent within 3 months prior to the first dose of study drug

- Having taken any gene therapy

- Other exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/04/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
19/10/2023
Sample size
Target
Accrual to date
Final
77
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Queensland Children's Hospital - Brisbane
Recruitment hospital [2] 0 0
Perth Children's Hospital - Nedlands
Recruitment hospital [3] 0 0
The Childrens Hospital at Westmead - Westmead
Recruitment postcode(s) [1] 0 0
- Brisbane
Recruitment postcode(s) [2] 0 0
- Nedlands
Recruitment postcode(s) [3] 0 0
- Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Illinois
Country [3] 0 0
Canada
State/province [3] 0 0
Ontario
Country [4] 0 0
Canada
State/province [4] 0 0
Calgary
Country [5] 0 0
Canada
State/province [5] 0 0
Quebec City
Country [6] 0 0
Chile
State/province [6] 0 0
Santiago
Country [7] 0 0
China
State/province [7] 0 0
Beijing
Country [8] 0 0
China
State/province [8] 0 0
Changsha
Country [9] 0 0
China
State/province [9] 0 0
Shanghai
Country [10] 0 0
China
State/province [10] 0 0
Shenzhen
Country [11] 0 0
Greece
State/province [11] 0 0
Athens
Country [12] 0 0
Greece
State/province [12] 0 0
Thessaloníki
Country [13] 0 0
Hong Kong
State/province [13] 0 0
Kowloon Bay
Country [14] 0 0
Italy
State/province [14] 0 0
Rome
Country [15] 0 0
Korea, Republic of
State/province [15] 0 0
Pusan
Country [16] 0 0
Korea, Republic of
State/province [16] 0 0
Seoul
Country [17] 0 0
Mexico
State/province [17] 0 0
Chihuahua
Country [18] 0 0
Mexico
State/province [18] 0 0
Ciudad de mexico
Country [19] 0 0
Netherlands
State/province [19] 0 0
Gelderland
Country [20] 0 0
Netherlands
State/province [20] 0 0
Leiden
Country [21] 0 0
New Zealand
State/province [21] 0 0
Auckland
Country [22] 0 0
Norway
State/province [22] 0 0
Oslo
Country [23] 0 0
Russian Federation
State/province [23] 0 0
Moscow
Country [24] 0 0
Russian Federation
State/province [24] 0 0
Saint Petersburg
Country [25] 0 0
Russian Federation
State/province [25] 0 0
Tomsk
Country [26] 0 0
Spain
State/province [26] 0 0
Barcelona
Country [27] 0 0
Spain
State/province [27] 0 0
Madrid
Country [28] 0 0
Taiwan
State/province [28] 0 0
Kaohsiung
Country [29] 0 0
Taiwan
State/province [29] 0 0
Taipei
Country [30] 0 0
Turkey
State/province [30] 0 0
Istanbul
Country [31] 0 0
Ukraine
State/province [31] 0 0
Kyiv
Country [32] 0 0
United Kingdom
State/province [32] 0 0
Birmingham
Country [33] 0 0
United Kingdom
State/province [33] 0 0
Glasgow
Country [34] 0 0
United Kingdom
State/province [34] 0 0
London
Country [35] 0 0
United Kingdom
State/province [35] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
NS Pharma, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Nippon Shinyaku Co., Ltd.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The main objective of this study is to evaluate the efficacy of Viltolarsen compared to
placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04060199
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04060199